Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Bausch + Lomb Co. (NYSE:BLCO - Get Rating) has received a consensus recommendation of "Moderate Buy" from the thirteen analysts that are currently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $23.42.

A number of research analysts recently weighed in on BLCO shares. Royal Bank of Canada reduced their target price on Bausch + Lomb from $22.00 to $18.00 and set an "outperform" rating on the stock in a report on Sunday, July 31st. Citigroup assumed coverage on Bausch + Lomb in a report on Monday, June 6th. They issued a "buy" rating and a $22.00 price objective for the company. JPMorgan Chase & Co. began coverage on Bausch + Lomb in a research note on Tuesday, May 31st. They issued a "neutral" rating and a $20.00 target price for the company. Morgan Stanley reduced their price objective on Bausch + Lomb from $22.00 to $20.00 and set an "equal weight" rating for the company in a research report on Thursday, June 9th. Finally, Wells Fargo & Company initiated coverage on Bausch + Lomb in a report on Tuesday, May 31st. They set an "overweight" rating and a $23.00 target price on the stock.Bausch + Lomb Stock Performance

BLCO stock opened at $15.75 on Thursday. Bausch + Lomb has a 52-week low of $12.20 and a 52-week high of $20.20. The business's fifty day simple moving average is $15.61. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.10 and a current ratio of 1.57.

Bausch + Lomb (NYSE:BLCO - Get Rating) last issued its earnings results on Wednesday, June 8th. The company reported $0.24 earnings per share for the quarter. The firm had revenue of $889.00 million during the quarter. Equities research analysts predict that Bausch + Lomb will post 1.08 EPS for the current fiscal year. Institutional Investors Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Strategic Wealth Partners Ltd. bought a new stake in shares of Bausch + Lomb during the 2nd quarter worth about $2,262,000. Legal & General Group Plc acquired a new stake in Bausch + Lomb in the 2nd quarter worth about $153,000. Goldman Sachs Group Inc. acquired a new position in shares of Bausch + Lomb in the 2nd quarter valued at approximately $1,937,000. Jane Street Group LLC acquired a new position in shares of Bausch + Lomb in the 2nd quarter valued at approximately $332,000. Finally, Penn Capital Management Company LLC acquired a new position in Bausch + Lomb during the 2nd quarter worth approximately $1,846,000. 10.32% of the stock is currently owned by institutional investors and hedge funds. Bausch + Lomb Company Profile (Get Rating)

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.Recommended StoriesGet a free copy of the StockNews.com research report on Bausch + Lomb (BLCO)3 High Margin Chipmakers Bound to Recover3 Solar Stocks That Will Benefit From the Biden Tariff Holiday REV Group Has A Deep Moat In The World Of EVs Is G-III Apparel Group, Ltd. A Value Trap? Bank Of America Sees Upside In These 2 European Alcohol Stocks

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Bausch + Lomb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.

While Bausch + Lomb currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Michael Wang of Prometheus Alternative Investments discusses how individuals should approach their portfolios as the summer rally seems to have fizzled.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.